Form 4: SI-BONE CFO Anshul Maheshwari Sells Shares Under 10b5-1 Trading Plan

Anshul Maheshwari, CFO of SI-BONE, Inc., executed a sale of common stock on May 12, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 12, 2025, Anshul Maheshwari, the Chief Financial Officer of SI-BONE, Inc., sold 4,937 shares of common stock.
• The sale was executed at a weighted-average price of $19.0249 per share, with individual transactions ranging from $19.00 to $19.14.
• The transaction was conducted under a 10b5-1 trading plan.
• Following the reported transaction, Maheshwari still beneficially owns 232,069 shares, including 180,329 shares issuable upon the settlement of restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive stock sale under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence, and the use of a 10b5-1 trading plan suggests the sale was pre-planned to avoid accusations of insider trading. It is important to monitor if other executives are selling shares.

Comparison to Industry Standards

• Executive stock sales are common across publicly traded companies, particularly in the healthcare sector.
• Companies like Stryker, Medtronic, and Zimmer Biomet also see regular Form 4 filings from their executives.
• The use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations, similar to what executives at Intuitive Surgical and Boston Scientific employ.

Stakeholder Impact

• The stock sale by a key executive could create short-term uncertainty among shareholders.
• However, the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

SI-BONE, Anshul Maheshwari, Form 4, Insider Trading, 10b5-1 Trading Plan, Chief Financial Officer, Stock Sale, Beneficial Ownership, Restricted Stock Units